
Keywords: Gb3; globotriaosylceramide; lyso-Gb3; globotriaosylsphingosine; α-GAL; alpha-galactosidase A; LVH; left ventricular hypertrophy; ERT; enzyme replacement therapy; CFDI; Canadian Fabry Disease Initiative; REB; Research Ethics Board; CHUS; Centre hospitalie